zinc finger and BTB domain containing 45 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored ZBTB45P2 profile across patient tissues and cancer cell-line models. ZBTB45P2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZBTB45P2 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, ZBTB45P2 RNA expression shows 6,284 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UVM, HNSC, and ESCA as cancer lineages where ZBTB45P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB45P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB45P2 survival associations across molecular data types. ZBTB45P2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB45P2 RNA expression–survival associations across cancer types. High ZBTB45P2 expression shows unfavorable associations in UVM, UCEC, THYM, MESO and KIRP, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZBTB45P2 RNA expression.
This table summarizes ZBTB45P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZBTB45P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB45P2 shows higher tumor expression in HNSC, STAD, LUAD, COAD, THCA and LUSC. The HNSC box plot shows higher ZBTB45P2 RNA expression in tumor versus normal tissue (log2 FC = +0.014, t-test p = .025).
This table shows molecular features associated with ZBTB45P2 in patient tissues and cancer cell lines. In patient samples, ZBTB45P2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
